M
Mary J. MacKenzie
Researcher at University of Western Ontario
Publications - 56
Citations - 6012
Mary J. MacKenzie is an academic researcher from University of Western Ontario. The author has contributed to research in topics: Renal cell carcinoma & Cancer. The author has an hindex of 27, co-authored 56 publications receiving 5332 citations. Previous affiliations of Mary J. MacKenzie include Juravinski Cancer Centre & London Health Sciences Centre.
Papers
More filters
Journal ArticleDOI
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann S. de Bono,Stéphane Oudard,Mustafa Ozguroglu,Steinbjørn Hansen,Jean-Pascal Machiels,Ivo Kocák,Gwenaelle Gravis,Istvan Bodrogi,Mary J. MacKenzie,Liji Shen,Martin Roessner,Sunil Gupta,A. Oliver Sartor +12 more
TL;DR: Treatment with cabazitaxel plus prednisone has important clinical antitumour activity, improving overall survival in patients with metastatic castration-resistant prostate cancer whose disease has progressed during or after docetaxel-based therapy.
Journal ArticleDOI
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
Daniel Y.C. Heng,Wanling Xie,Meredith M. Regan,Lauren C. Harshman,Georg A. Bjarnason,Ulka N. Vaishampayan,Mary J. MacKenzie,Lori Wood,Frede Donskov,Min-Han Tan,Sun Young Rha,Neeraj Agarwal,Christian Kollmannsberger,Brian I. Rini,Toni K. Choueiri +14 more
TL;DR: The Database Consortium model is now externally validated and can be applied to stratify patients by risk in clinical trials and to counsel patients about prognosis.
Journal ArticleDOI
Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study
Sebastien J. Hotte,Eric Winquist,Elizabeth B. Lamont,Mary J. MacKenzie,Everett E. Vokes,Eric Chen,Shirley Brown,Gregory R. Pond,Anthony J. Murgo,Lillian L. Siu +9 more
TL;DR: The study has been stopped after the first stage and additional evaluation of imatinib in this population is not warranted because of the lack of activity, and overexpression of wild-type c-kit was not sufficient for clinical benefit from imatinIB in ACC.
Journal ArticleDOI
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.
Rana R. McKay,Nils Kroeger,Nils Kroeger,Wanling Xie,Jae-Lyun Lee,Jennifer J. Knox,Georg A. Bjarnason,Mary J. MacKenzie,Lori Wood,Sandy Srinivas,Ulka N. Vaishampayan,Sun Young Rha,Sumanta K. Pal,Frede Donskov,Srinivas K. Tantravahi,Brian I. Rini,Daniel Y.C. Heng,Toni K. Choueiri +17 more
TL;DR: The presence of bone metastases and LMs in patients treated with targeted agents has a negative impact on survival and patients with BMs and/or LMs may benefit from earlier inclusion on clinical trials of novel agents or combination-based therapies.
Journal ArticleDOI
Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria
Nils Kroeger,Wanling Xie,Jae Lyn Lee,Georg A. Bjarnason,Jennifer J. Knox,Mary J. MacKenzie,Lori Wood,Sandy Srinivas,Ulka N. Vaishamayan,Sun Young Rha,Sumanta K. Pal,Takeshi Yuasa,Frede Donskov,Neeraj Agarwal,Christian Kollmannsberger,Min-Han Tan,Scott North,Brian I. Rini,Toni K. Choueiri,Daniel Y.C. Heng +19 more
TL;DR: This study aimed to apply the International mRCC Database Consortium prognostic model in metastatic non–clear cell renal cell carcinoma (nccRCC) and the survival outcome of metastatic nCCRCC patients was characterized.